



Programme
COST Action ENOTTA CA21147
2nd International Conference
10th-12th December 2025, Madrid (Spain)

Scientific organisation:

George Kararigas
University of Nicosia - Athens

Host & local scientific organisation:

M^a José Martínez Becerra
Hospital Universitario Fundación Jiménez Díaz

Venue:

Hospital Universitario Fundación Jiménez Díaz - Aula Eloy López
Avda. de los Reyes Católicos 2
28040 Madrid, Spain

<https://maps.app.goo.gl/Mqx5zERhRXw9ALwx6>

Metro stations: Islas Filipinas (line 7), Moncloa (lines 3 and 6)

DAY 1: 10th December 2025

09:00 - 09:30 Registration

09:30 - 09:45 Welcome & opening remarks

Denis Mulleman, M^a José Martínez Becerra, George Kararigas

09:45 - 10:45 Management Committee (MC) meeting with ENOTTA overview - *hybrid*

Chair(s): Nataša Bogavac-Stanojević, Speaker(s): **Denis Mulleman**

10:45 - 11:00 Group photo

11:00 - 11:30 Coffee break

11:30 - 13:00 Scientific Session 1 (15 min talk + 5 min discussion)

Chair(s): M^a José Martínez Becerra

Dora Pascual (ES): From samples to a European network: a story behind Therapeutic Drug Monitoring in inflammatory diseases

Ana Martinez Feito (ES): Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures and on clinical response in patients with RA

Andrea Ortiz Domínguez (ES): From Doses to Decisions: Our Experience Navigating Therapeutic Drug Monitoring in a Tertiary Hospital

May Villar (ES): Therapeutic Drug Monitoring in Multiple Sclerosis

Simon Daviere (ES): Standardizing Anti-Drug Antibody Assays: Impact of the First WHO International Standard for Anti-Infliximab from the industry perspective

13:00 - 14:00 Lunch break

14:00 - 15:30 Scientific Session 2 (15 min talk + 5 min discussion)

Chair(s): Elena Kkolou

Wei Zhang (BE): Population pharmacokinetic model of ustekinumab in patients with chronic pouchitis

Anke Eylenbosch (BE): Development of a population PK-PD model for secukinumab in psoriasis

My-Luong Vuong (BE): Precision dosing of infliximab in patients with inflammatory bowel diseases

Emmanuel Niyigena (BE): Model-Informed precision dosing during infliximab rescue therapy for patients with steroid-refractory acute severe ulcerative colitis: an Exploratory study

15:30 - 16:00 Coffee break

16:00 - 17:00 Video filming

Involved participants only

20:15 - 23:00 Conference dinner generously sponsored by Biosynex

La huerta de Tudela; Calle Prado 15, Madrid

<https://www.lahuertadetudela.com> / <https://share.google/3M4ceMqcesSF3jgUx>



ENOTTA 2nd International Conference
10th-12th December 2025, Madrid (Spain)

DAY 2: 11th December 2025

09:00 - 09:30 Registration

09:30 - 11:00 Scientific Session 3 (15 min talk + 5 min discussion)

Chair(s): Denis Mulleman

Aleksandra Catic Dordevic (RS): Precision in Practice: Biologic Antibodies Reshaping Psoriasis Care

Sara Sottile (IT): Methotrexate's Effect on Cells and Adalimumab Immunogenicity in Axial Spondyloarthritis: A Mathematical Study

Bechara Saade (CZ): Understanding the role of Methotrexate polyglutamate in modulating adalimumab immunogenicity: a mathematical approach

Vesna Cuplov (FR) Predicting immunogenicity to Infliximab or Adalimumab using machine learning techniques (*online*)

11:00 - 11:30 Coffee break

11:30 - 12:30 Scientific Session 4 (15 min talk + 5 min discussion)

Chair(s): Nataša Bogavac-Stanojević

Meghna Jani (UK): Development of an international guideline on therapeutic drug monitoring across chronic inflammatory diseases

Hannah Shafi (UK): A Systematic Review of the Differences Between Available TDM Assays for biological therapeutics in IMIDs: A Working Group 3 ENOTTA project

James Bluett/Sean Gavan (UK): Signing a Trial of Biologic Drug Level-guided Tapering to Inform UK National Policy for IMIDs

12:30 - 13:30 Lunch break

13:30 - 22:00 Social networking and informal discussions

DAY 3: 12th December 2025

08:30 - 09:00 Registration

09:00 - 10:30 Scientific Session 5 (15 min talk + 5 min discussion)

Chair(s): Meghna Jani

Denis Mulleman (FR): Anti CD20 antibody Rituximab effect on B and T lymphocytes in rheumatoid arthritis

Nikola Stefanovic (RS): The Role of microRNAs as Potential Biomarkers in Chronic Inflammation

Dejan Dobrijević (RS): Reliability of ELISA in Therapeutic Drug Monitoring of Adalimumab and Infliximab in Pediatric Inflammatory Bowel Disease

Albino Martins (PT): Capturing drug delivery systems as a strategy to locally control inflammatory arthritic diseases

10:30 - 11:00 Coffee break

11:00 - 12:00 Scientific Session 6 (15 min talk + 5 min discussion)

Chair(s): Mehmet İtik

Katarina Vucicevic (RS): Real-World Evidence on the Safety of Vedolizumab in Inflammatory Bowel Disease: Insights from Post-Marketing Data

Rani Soenen (BE): Dose reduction of the new generation biologics (interleukin 17 and interleukin 23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio study

Frans Kokojka (IL): Do we need more efficient assays for ADA measurement? - Emerging biosensors and presentation of the first disruptive drug-tolerant POC diagnostic

12:00 - 13:00 Spotlight issue progress report/updates (15 min each)

Chair(s): Denis Mulleman

Speaker(s): **WG1-WG4 leaders/co-leaders**

13:00 - 14:00 Lunch break

14:00 - 15:00 Video filming

Involved participants only